United States
Print page content Print
Increase text size Decrease text size
Text Size

FarrowSure® GOLD

FARROWSURE® GOLD

When protecting sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas — you can count on FarrowSure® GOLD and FarrowSure® GOLD B to provide:

  • Dependable performance
  • Safety
  • Efficacy
  • Reliable support and supply
  • Healthier pigs
Expand All
  • FarrowSure GOLD and FarrowSure GOLD B are approved for use in healthy breeding swine as an aid in preventing reproductive failure caused by porcine parvovirus (PPV); erysipelas caused by Erysipelothrix rhusiopathiae; and leptospirosis caused by Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. FarrowSure GOLD B helps protect against L. bratislava.

    Count on dependable performance

    • Both FarrowSure GOLD and FarrowSure GOLD B contain two adjuvants, including Amphigen®, which enhances the immune response using the animal’s natural defense system to fight disease.
    • In two field safety studies where more than 400 gestating sows and gilts were vaccinated with FarrowSure GOLD B in combination with FluSure XP®, there were no abortions observed in the vaccinated animals.1,2

    Count on safety

    • Three field safety studies involving 205 pre-breeding gilts and 406 gestating sows and gilts indicated that two doses of FarrowSure GOLD B, in combination with FluSure XP, can be safely administered to pre-breeding gilts and that a dose can be safely given to pregnant sows as late as two to four weeks prior to farrowing (73 to 101 days of gestation).1-3
    • In a field safety study conducted in pre-breeding gilts, injection site reactions were rare.3 Results were similar in gestating sows and gilts — when administered according to label directions to pregnant sows and gilts at two to four weeks prior to farrowing, reactions were minimal in number, of little consequence in severity and transient in duration.1,2

    Count on efficacy

    • FarrowSure GOLD and FarrowSure GOLD B provide clinically demonstrated 18-week post-vaccination duration of immunity against erysipelas caused by Erysipelothrix rhusiopathiae.4

    Count on reliable support and supply

    • Because FarrowSure® GOLD and FarrowSure GOLD B are manufactured and supplied by Zoetis, you can count on renowned technical support and customer service, and a consistent, uninterrupted supply.

    Count on healthier pigs

    • FarrowSure GOLD and FarrowSure GOLD B help protect against some of the leading causes of reproductive failure in swine. Bottom line: You are helping ensure production of healthier pigs.

    References

    1 Data on file, Study Report No. 3427R-60-06-396, Zoetis Inc.
    2 Data on file, Study Report No. 3427R-60-06-397, Zoetis Inc.
    3 Data on file, Study Report No. 3427R-60-06-398, Zoetis Inc.
    4 Data on file, Study Report No. 3121R-60-05-339, Zoetis Inc.

  • Packaging:

    • FarrowSure GOLD — 50- and 250-dose vials
    • FarrowSure GOLD B — 50-dose vial

    Directions:

    1. General directions: Shake well. Aseptically administer 2 mL intramuscularly.
    2. Primary vaccination: Healthy swine should receive two doses three to five weeks apart with the second dose administered two to four weeks prior to breeding. Healthy gilts, however, should receive the second dose as near as possible to 14 days prior to breeding.
    3. Revaccination: Revaccination with a single dose is recommended prior to subsequent breedings. Boars should be revaccinated semiannually.
    4. Good animal husbandry and herd health management practices should be employed.

    Precautions:

    1. Store at 2° to 7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
    2. Use entire contents when first opened.
    3. Sterilized syringes and needles should be used to administer this vaccine.
    4. Do not vaccinate within 21 days before slaughter.
    5. Contains gentamicin as a preservative.
    6. Transient injection-site swelling and/or inappetence may occur following vaccination.
    7. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
    8. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

FRW-00003